SEC Form 4 · STOCK Act

Insider buys that paid off for the people who copied them.

$ZSTK

ZeroStack Corp.

+206.0%

Michael Heinrich, Executive Chair, bought $3.5M. Filed Jul 20, 6:31 PM ET.

COPIED JUL 21

$1,000 copied at the first price after the filing (Jul 21 open, $1.66) was $3,060 30 trading days later.

Example. Of 339 buys of $100K or more filed Jun 29 to Sep 11, the median lost 5.3% and 67.8% lost money over the same 30 trading days. Not investment advice.

Officers and directors must report their own stock purchases within two business days. We list every one, largest first, with what copying it would have returned.

A free account keeps a watchlist. No password: we email you a link.

ITCISell

Intra-Cellular Therapies, Inc.

Michael Halstead · President

$3.7M−100.0%Nov 14
ITCISell

Intra-Cellular Therapies, Inc.

Sharon Mates · Chair and CEO

$5.1M−6.0%Aug 30
ITCISell

Intra-Cellular Therapies, Inc.

Sharon Mates · Chair and CEO

$7.1M−8.0%Aug 28
ITCISell

Intra-Cellular Therapies, Inc.

Sharon Mates · Chair and CEO

$9.1M−10.0%Aug 23
ITCISell

Intra-Cellular Therapies, Inc.

Mark Neumann · EVP and Chief Commercial Officer

$1.4M−39.0%Aug 20
ITCISell

Intra-Cellular Therapies, Inc.

Rory B Riggs · Director

$337K−4.0%Jun 25
ITCISell

Intra-Cellular Therapies, Inc.

Nostrand Robert L Van · Director

$1.5M−67.0%Jun 21
ITCISell

Intra-Cellular Therapies, Inc.

Sharon Mates · Chair, President and CEO

$4.0M−6.0%Mar 11
ITCISell

Intra-Cellular Therapies, Inc.

Lawrence J. Hineline · SVP of Finance, CFO

$1.5M−100.0%Mar 11
ITCISell

Intra-Cellular Therapies, Inc.

Michael Halstead · EVP and General Counsel

$1.4M−100.0%Mar 11
ITCISell

Intra-Cellular Therapies, Inc.

Mark Neumann · EVP and Chief Commercial Officer

$1.4M−41.0%Mar 11
ITCISell

Intra-Cellular Therapies, Inc.

Suresh K. Durgam · EVP and Chief Medical Officer

$673K−34.0%Mar 11
ITCISell

Intra-Cellular Therapies, Inc.

Nostrand Robert L Van · Director

$1.5M−68.0%Feb 28
ITCISell

Intra-Cellular Therapies, Inc.

Sharon Mates · Chair, President and CEO

$1.6M−2.0%Feb 27
ITCISell

Intra-Cellular Therapies, Inc.

Joel S Marcus · Director

$1.8M−35.0%Feb 27
ITCISell

Intra-Cellular Therapies, Inc.

Michael Halstead · EVP and General Counsel

$550K−100.0%Feb 27
ITCISell

Intra-Cellular Therapies, Inc.

Lawrence J. Hineline · SVP of Finance, CFO

$926K−100.0%Feb 27
ITCISell

Intra-Cellular Therapies, Inc.

Suresh K. Durgam · EVP and Chief Medical Officer

$289K−30.0%Feb 27
ITCISell

Intra-Cellular Therapies, Inc.

Mark Neumann · EVP and Chief Commercial Officer

$554K−21.0%Feb 27
ITCISell

Intra-Cellular Therapies, Inc.

Sharon Mates · Chair, President and CEO

$2.3M−3.0%Feb 5
ITCISell

Intra-Cellular Therapies, Inc.

Michael Halstead · EVP and General Counsel

$788K−100.0%Feb 5
ITCISell

Intra-Cellular Therapies, Inc.

Mark Neumann · EVP and Chief Commercial Officer

$796K−29.0%Feb 5
ITCISell

Intra-Cellular Therapies, Inc.

Lawrence J. Hineline · SVP of Finance, CFO

$745K−100.0%Feb 5
ITCISell

Intra-Cellular Therapies, Inc.

Suresh K. Durgam · EVP and Chief Medical Officer

$414K−52.0%Feb 5
ITCISell

Intra-Cellular Therapies, Inc.

Sharon Mates · Chair, President and CEO

$12.7M−15.0%Jan 18
ITCISell

Intra-Cellular Therapies, Inc.

Michael Halstead · EVP and General Counsel

$3.3M−100.0%Jan 12
ITCISell

Intra-Cellular Therapies, Inc.

Suresh K. Durgam · EVP and Chief Medical Officer

$4.4M−100.0%Jan 4
ITCISell

Intra-Cellular Therapies, Inc.

Suresh K. Durgam · EVP and Chief Medical Officer

$1.4M−100.0%Dec 15
ITCISell

Intra-Cellular Therapies, Inc.

Mark Neumann · EVP and Chief Commercial Officer

$2.4M−59.0%Nov 8
ITCISell

Intra-Cellular Therapies, Inc.

Sharon Mates · Chair, President and CEO

$5.4M−9.0%Sep 19
ITCISell

Intra-Cellular Therapies, Inc.

Mark Neumann · EVP and Chief Commercial Officer

$3.3M−55.0%Aug 9
ITCISell

Intra-Cellular Therapies, Inc.

Suresh K. Durgam · EVP and Chief Medical Officer

$120K−8.0%Jul 20
ITCISell

Intra-Cellular Therapies, Inc.

Lawrence J. Hineline · SVP of Finance CFO

$5.2M−100.0%Jun 16
ITCISell

Intra-Cellular Therapies, Inc.

Nostrand Robert L Van · Director

$630K−52.0%Apr 19
ITCISell

Intra-Cellular Therapies, Inc.

Mark Neumann · EVP and Chief Commercial Officer

$847K−26.0%Mar 30
ITCISell

Intra-Cellular Therapies, Inc.

Sharon Mates · Chair, President and CEO

$2.7M−5.0%Mar 13
ITCISell

Intra-Cellular Therapies, Inc.

Suresh K. Durgam · EVP and Chief Medical Officer

$331K−24.0%Mar 13
ITCISell

Intra-Cellular Therapies, Inc.

Mark Neumann · EVP and Chief Commercial Officer

$540K−17.0%Mar 13
ITCISell

Intra-Cellular Therapies, Inc.

Michael Halstead · EVP and General Counsel

$1.1M−100.0%Mar 13
ITCISell

Intra-Cellular Therapies, Inc.

Lawrence J. Hineline · SVP of Finance CFO

$925K−100.0%Mar 13
ITCISell

Intra-Cellular Therapies, Inc.

Mark Neumann · EVP and Chief Commercial Officer

$362K−13.0%Mar 3
ITCISell

Intra-Cellular Therapies, Inc.

Sharon Mates · Chair, President and CEO

$1.1M−2.0%Feb 27
ITCISell

Intra-Cellular Therapies, Inc.

Mark Neumann · EVP and Chief Commercial Officer

$191K−7.0%Feb 27
ITCISell

Intra-Cellular Therapies, Inc.

Suresh K. Durgam · SVP and Chief Medical Officer

$373K−25.0%Feb 27
ITCISell

Intra-Cellular Therapies, Inc.

Michael Halstead · EVP and General Counsel

$372K−100.0%Feb 27
ITCISell

Intra-Cellular Therapies, Inc.

Lawrence J. Hineline · SVP of Finance CFO

$351K−100.0%Feb 27
ITCISell

Intra-Cellular Therapies, Inc.

Sharon Mates · Chair, President and CEO

$1.3M−2.0%Feb 22
ITCISell

Intra-Cellular Therapies, Inc.

Mark Neumann · EVP and Chief Commercial Officer

$183K−7.0%Feb 22
ITCISell

Intra-Cellular Therapies, Inc.

Suresh K. Durgam · SVP and Chief Medical Officer

$391K−27.0%Feb 22
ITCISell

Intra-Cellular Therapies, Inc.

Michael Halstead · EVP and General Counsel

$522K−100.0%Feb 22

Filings come from SEC EDGAR within a minute of the SEC accepting them. Without Pro, each one unlocks 4 hours later. Not investment advice.

Questions

Where does the data come from?

Corporate insider trades come straight from SEC Form 4 filings, pulled from EDGAR within a minute of each filing. Congress trades come from STOCK Act disclosures. All of it is public and free to browse here, and Pro sees the newest filings first.

How often is it updated?

Every minute from 6 AM to 10 PM New York time on weekdays, the hours the SEC accepts filings. Pro sees each filing as it lands. Without Pro, a filing unlocks 4 hours after the SEC accepts it.

Is following insider trades legal?

Yes. Insiders are legally required to disclose their trades within a few days. Acting on those public disclosures is completely legal. Trading on private, non-public information is illegal, but that's a different thing.

What does the iPhone app add?

We're building an iPhone app that alerts you to new filings and, if you choose, copies a buy into your own brokerage after you approve it. It isn't out yet, and the waitlist is free.